151 related articles for article (PubMed ID: 3019721)
1. Stereospecific binding of the antidepressant rolipram to brain protein structures.
Schneider HH; Schmiechen R; Brezinski M; Seidler J
Eur J Pharmacol; 1986 Aug; 127(1-2):105-15. PubMed ID: 3019721
[TBL] [Abstract][Full Text] [Related]
2. Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram.
Kaulen P; Brüning G; Schneider HH; Sarter M; Baumgarten HG
Brain Res; 1989 Dec; 503(2):229-45. PubMed ID: 2557965
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
[TBL] [Abstract][Full Text] [Related]
4. CDP840: a novel inhibitor of PDE-4.
Perry MJ; O'Connell J; Walker C; Crabbe T; Baldock D; Russell A; Lumb S; Huang Z; Howat D; Allen R; Merriman M; Walls J; Daniel T; Hughes B; Laliberte F; Higgs GA; Owens RJ
Cell Biochem Biophys; 1998; 29(1-2):113-32. PubMed ID: 9631241
[TBL] [Abstract][Full Text] [Related]
5. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.
Souness JE; Maslen C; Webber S; Foster M; Raeburn D; Palfreyman MN; Ashton MJ; Karlsson JA
Br J Pharmacol; 1995 May; 115(1):39-46. PubMed ID: 7647982
[TBL] [Abstract][Full Text] [Related]
6. Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase.
Souness JE; Scott LC
Biochem J; 1993 Apr; 291 ( Pt 2)(Pt 2):389-95. PubMed ID: 8387267
[TBL] [Abstract][Full Text] [Related]
7. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast.
Torphy TJ; Stadel JM; Burman M; Cieslinski LB; McLaughlin MM; White JR; Livi GP
J Biol Chem; 1992 Jan; 267(3):1798-804. PubMed ID: 1309798
[TBL] [Abstract][Full Text] [Related]
8. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
Jacobitz S; McLaughlin MM; Livi GP; Burman M; Torphy TJ
Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
[TBL] [Abstract][Full Text] [Related]
9. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors.
Wachtel H
Neuropharmacology; 1983 Mar; 22(3):267-72. PubMed ID: 6302550
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of rolipram on partially purified phosphodiesterase 4 from rat brains.
Ohsawa F; Yamauchi M; Nagaso H; Murakami S; Baba J; Sawa A
Jpn J Pharmacol; 1998 Jun; 77(2):147-54. PubMed ID: 9681571
[TBL] [Abstract][Full Text] [Related]
11. Age-related changes in [3H]nimodipine and [3H]rolipram binding in the rat brain.
Araki T; Kato H; Shuto K; Itoyama Y
J Pharm Pharmacol; 1997 Mar; 49(3):310-4. PubMed ID: 9231352
[TBL] [Abstract][Full Text] [Related]
12. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate.
Tian G; Rocque WJ; Wiseman JS; Thompson IZ; Holmes WD; Domanico PL; Stafford JA; Feldman PL; Luther MA
Biochemistry; 1998 May; 37(19):6894-904. PubMed ID: 9578576
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.
Barnette MS; Grous M; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 Jun; 273(3):1396-402. PubMed ID: 7791113
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram.
Zhao Y; Zhang HT; O'Donnell JM
J Pharmacol Exp Ther; 2003 May; 305(2):565-72. PubMed ID: 12704225
[TBL] [Abstract][Full Text] [Related]
16. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
[TBL] [Abstract][Full Text] [Related]
17. Neurotropic effects of the optical isomers of the selective adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo.
Wachtel H
J Pharm Pharmacol; 1983 Jul; 35(7):440-4. PubMed ID: 6136585
[TBL] [Abstract][Full Text] [Related]
18. Sequential alterations of [3H]rolipram and [3H]cyclic adenosine monophosphate binding in the gerbil brain following transient cerebral ischemia.
Murase K; Kato H; Araki T; Kogure K
Brain Res; 1993 Feb; 602(2):234-9. PubMed ID: 8383573
[TBL] [Abstract][Full Text] [Related]
19. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
Christensen SB; Guider A; Forster CJ; Gleason JG; Bender PE; Karpinski JM; DeWolf WE; Barnette MS; Underwood DC; Griswold DE; Cieslinski LB; Burman M; Bochnowicz S; Osborn RR; Manning CD; Grous M; Hillegas LM; Bartus JO; Ryan MD; Eggleston DS; Haltiwanger RC; Torphy TJ
J Med Chem; 1998 Mar; 41(6):821-35. PubMed ID: 9526558
[TBL] [Abstract][Full Text] [Related]
20. Isolation of similar rolipram-inhibitable cyclic-AMP-specific phosphodiesterases from rat brain and heart.
Némoz G; Moueqqit M; Prigent AF; Pacheco H
Eur J Biochem; 1989 Oct; 184(3):511-20. PubMed ID: 2553394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
